SCHEMBL11304570

SCHEMBL11304570

Cn1c(=O)nc(N)c2[nH]cnc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.54
ADORA2A P29274 8/20 0.53
PDE4A P27815 8/20 0.53
PDE4B Q07343 8/20 0.53
PDE4C Q08493 8/20 0.53
PDE4D Q08499 8/20 0.53
ADORA2B P29275 8/20 0.53
ADORA3 P0DMS8 3/20 0.53
ADORA1 P30542 2/20 0.53
PIK3CD O00329 1/20 0.53
ALPL P05186 1/20 0.53
TMIGD3 P0DMS9 1/20 0.53
CYP2C19 P33261 1/20 0.53
HIF1A Q16665 1/20 0.53
CYP1A2 P05177 2/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
CFTR P13569 2/20 0.44
PDPK1 O15530 1/20 0.42
GDA Q9Y2T3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Methylxanthine SCHEMBL8663339 0.81 ATAD2 (0.53) ATAD2ADORA2APDE4APDE4BPDE4C
SCHEMBL48434 0.75 ATAD2 (0.54) ATAD2ADORA2APDE4APDE4BPDE4C
SCHEMBL31685567 0.74 PNP (0.49) ATAD2ADORA2APDE4APDE4BPDE4C
SCHEMBL27923861 0.71 PDE4A (0.42) ADORA2APDE4APDE4BPDE4CPDE4D
Theophylline Anhydrous SCHEMBL25398274 0.70 ATAD2 (1.00) ATAD2ADORA2APDE4APDE4BPDE4C
Theophylline Anhydrous SCHEMBL3051675 0.70 ATAD2 (1.00) ATAD2ADORA2APDE4APDE4BPDE4C
Theophylline Anhydrous SCHEMBL8595167 0.70 ATAD2 (1.00) ATAD2ADORA2APDE4APDE4BPDE4C
Theophylline Anhydrous SCHEMBL4915 0.70 ATAD2 (1.00) ATAD2ADORA2APDE4APDE4BPDE4C
Theophylline Anhydrous SCHEMBL1274777 0.69 ATAD2 (0.96) ATAD2ADORA2APDE4APDE4BPDE4C
Theophylline Anhydrous SCHEMBL5454758 0.69 ATAD2 (0.96) ATAD2ADORA2APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-56051481-A None JP disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 US disclosed
JP-S5651481-A 6-CYANO-2-OXO-3-METHYL-2,3-DIHYDROPURINE SAGAMI CHEM RES CENTER 1981-05-09 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 ATAD2 4633/4885ADORA2A 593/4885PDE4A 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.